IPP Bureau
Jubilant Ingrevia appoints Birajeev Suresh Singh as SVP – Supply Chain
By IPP Bureau - September 03, 2024
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
Lupin launches Doxorubicin Hydrochloride Liposome Injection in US
By IPP Bureau - September 03, 2024
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
Roche’s PiaSky approved in the EU for treatment of people with PNH
By IPP Bureau - September 03, 2024
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Tolebrutinib meets primary endpoint in HERCULES phase 3 study
By IPP Bureau - September 03, 2024
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure
By IPP Bureau - September 02, 2024
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
Merck announces first patient dosed in Phase III study of Oral Cladribine in gMG
By IPP Bureau - September 02, 2024
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Govt. to improve availability of infrastructure and trained manpower for organ transplantation
By IPP Bureau - September 01, 2024
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
Mitsubishi Chemical's clinical study demonstrates effectiveness of probiotic on intestinal environment
By IPP Bureau - September 01, 2024
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Biocon Pharma receives USFDA approval for daptomycin
By IPP Bureau - September 01, 2024
The approval further adds to Biocon’s portfolio of complex drug products
Zydus receives warning letter from USFDA for Jarod injectables manufacturing facility
By IPP Bureau - August 31, 2024
The company will take all necessary steps to work with USFDA towards earliest remediation of the above facility
Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
By IPP Bureau - August 31, 2024
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
DKSH partners with Hasten Biopharmaceutical’s growth in Thailand
By IPP Bureau - August 31, 2024
Indian doctor participates in Jordan’s first robotic radical hysterectomies
By IPP Bureau - August 31, 2024
Biocon Biologics secures market entry for Bmab 1200 in Europe, UK, Canada, and Japan
By IPP Bureau - August 30, 2024
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
